Trial Profile
A Double-Blind, Placebo Controlled, Randomized, Two Centre Phase IIA Pharmacodynamic Cross-Over Study to Assess the Effect of AZD3355, 65 mg Bid, on Transient Lower Esophageal Sphincter Relaxations (TLESRs) in GERD Patients With an Incomplete Response to PPI Treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Lesogaberan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 05 May 2010 Results published in Gastroenterology.
- 17 Nov 2009 Results to be presented at the GASTRO 2009 joint meeting (UEGW/WCOG).
- 12 Jun 2009 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.